T cell activator STAR0602 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Ear, nose & throat, Infections, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that cannot be surgically removed or has spread, and standard treatments are no longer working or are not tolerable.
- You should not have had more than three prior cancer treatments (for the first part of the study, no more than one prior treatment for some groups).
- For the first phase, your tumor type must be one of: high mutation burden (TMB-H), MSI-H/dMMR, a virus-related tumor, or a type considered highly responsive to immunotherapy (like melanoma or kidney cancer).
- If you had brain metastases, they must have been treated, not causing symptoms for at least 14 days, and you must not be on strong steroids or other treatments for them.
- If you previously had immunotherapy, any side effects must have resolved, except for hormone-related issues controlled with replacement therapy.
- You cannot have an active autoimmune disease beyond certain exceptions, no major surgery or unhealed wounds, and no serious heart, lung, or digestive conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (SYS6006) combined with an existing immunotherapy (called Enlonstobart) to see if it works better than the immunotherapy alone for people with advanced solid tumors. It may help shrink or slow the growth of your cancer.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
Hear when a new Urogenital Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.